SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Decibel Therapeutics, Inc. (Nasdaq – DBTX)

BALA CYNWYD – August 9, 2023 /Globe Newswire/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Decibel Therapeutics, Inc. (“Decibel” or the “Company”) (Nasdaq – DBTX) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Regeneron Pharmaceuticals, Inc. (Nasdaq – REGN). Under the terms of the Agreement, Decibel shareholders will receive $4.00 per share of Decibel common stock payable in cash at closing, with an additional non-tradeable contingent value right (CVR) to receive up to $3.50 per share in cash upon achievement of certain clinical development and regulatory milestones for Decibel’s lead investigational candidate, DB-OTO, within specified time periods. The proposed acquisition values Decibel at a total equity value of approximately $109 million based on the amount payable at closing, and a total equity value of up to approximately $213 million if the CVR milestones are achieved.

The investigation concerns whether the Decibel Board breached its fiduciary duties to shareholders by failing to conduct a fair process resulting in Regeneron paying less than full value for the Company.

If you own shares of Decibel stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, by email at, or call toll free 855-576-4847.